2026-04-17T19:29:00Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1860792025-12-05T13:17:57Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048 Rischin, Danny Harrington, Kevin J. Greil, Richard Soulières, Denis Tahara, Makoto Castro, Gilberto de Psyrri, Amanda Braña, Irene Neupane, Prakash Bratland, Åse Fuereder, Thorsten Hughes, Brett G.M. Mesía Nin, Ricard Ngamphaiboon, Nuttapong Rordorf, Tamara Ishak, Wan Zamaniah Wan Hong, Ruey-Long Gonzalez Mendoza, René Jia, Liyi Chirovsky, Diana Norquist, Josephine Jin, Fan Burtness, Barbara Càncer Tractament del dolor Cancer Pain treatment Objectives: To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumabchemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the phase 3 KEYNOTE-048 trial (NCT02358031).& nbsp;Materials and Methods: HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H & N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L). Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H & N35 pain and swallowing.& nbsp;Results: Of 882 enrolled participants, 844 received > 1 dose of study treatment and completed > 1 HRQoL assessment; adherence was > 79% at week 15 across treatment groups. At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI,-3.34 to 3.82; pembrolizumabchemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI,-3.46 to 4.26). Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H & N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL. TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximabchemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H & N35 pain and swallowing scores.& nbsp;Conclusions: Pembrolizumab monotherapy and pembrolizumab-chemotherapy extended OS while maintaining HRQoL, further supporting first-line use for R/M HNSCC. 2022-05-27T08:04:32Z 2022-05-27T08:04:32Z 2022-05-01 2022-05-26T10:43:17Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1368-8375 https://hdl.handle.net/2445/186079 35381576 732735 eng Reproducció del document publicat a: https://doi.org/10.1016/j.oraloncology.2022.105815 Oral Oncology, 2022, vol. 128 https://doi.org/10.1016/j.oraloncology.2022.105815 cc by-nc-nd (c) Rischin, Danny et al, 2022 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess 12 p. application/pdf Elsevier Articles publicats en revistes (Ciències Clíniques)